Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
At a glance
Conditions
NCT07640555
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Institute for Neurodegenerative Disorders and XingImaging, LLC
New Haven, Connecticutstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Standard Uptake Value Ratios (SUVR)Up to 3 hours after tracer injection.
To evaluate Standard Uptake Value Ratios (SUVR) in brain regions from \[18F\]MODAG-009 in participants with PD.
- Standard Uptake Value Ratios (SUVR)Up to 3 hours after tracer injection.
To evaluate Standard Uptake Value Ratios (SUVR) in brain regions from \[18F\]MODAG-009 in participants with MSA.
- Standard Uptake Value Ratios (SUVR)Up to 3 hours after tracer injection.
To evaluate Standard Uptake Value Ratios (SUVR) in brain regions from \[18F\]MODAG-009 in HC participants.